title: (18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma.
abstract: BACKGROUND
  Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared (18)F-fluoride-PET with the MAR in myeloma patients.
  
  
  METHODS
  Bone formation was measured before and after bortezomib treatment by determination of the MAR in iliac bone marrow biopsies and the measurement of (18)F-uptake.
  
  
  RESULTS
  The inter- and intra-individual variations in (18)F-uptake (SUVA50%) were pronounced as 33.50 (range 4.42 to 37.92) and 27.18 (range 4.00 to 31.18), respectively. A significant correlation between the MAR and (18)F-uptake was found (r = 0.80, p = 0.017). There was a heterogeneous response after treatment varying from -2.20 to 4.53.
  
  
  CONCLUSIONS
  Iliac (18)F-uptake was associated with the local MAR in myeloma patients. Furthermore, (18)F-fluoride-PET demonstrated the heterogeneity of in vivo bone formation, enabling monitoring during treatment.
authors.affiliation: Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands. jc.regelink@meandermc.nl.|Department of Internal Medicine, Meander Medical Centre, Amersfoort, The Netherlands. jc.regelink@meandermc.nl.
authors.forename: J C
authors.initials: JC
authors.lastname: Regelink
authors.affiliation: Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: P G
authors.initials: PG
authors.lastname: Raijmakers
authors.affiliation: Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: N
authors.initials: N
authors.lastname: Bravenboer
authors.affiliation: Janssen-Cilag B.V., Tilburg, The Netherlands.
authors.forename: R
authors.initials: R
authors.lastname: Milek
authors.affiliation: Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: N J
authors.initials: NJ
authors.lastname: Hoetjes
authors.affiliation: Department of Internal Medicine, Sint Lucas Andreas Hospital, Amsterdam, The Netherlands.
authors.forename: A M
authors.initials: AM
authors.lastname: de Kreuk
authors.affiliation: Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: van Duin
authors.affiliation: Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: Wondergem
authors.affiliation: Endocrine Section, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: P
authors.initials: P
authors.lastname: Lips
authors.affiliation: Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
authors.forename: P
authors.initials: P
authors.lastname: Sonneveld
authors.affiliation: Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: J M
authors.initials: JM
authors.lastname: Zijlstra
authors.affiliation: Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: S
authors.initials: S
authors.lastname: Zweegman